AKT1 and cancer: Biological cancer target therapy is those cell signaling pathways, including survival signaling (e.g., phosphatidylinositide 3-kinases- (PI3K-) Akt/protein kinase B (PKB)); cell cycle proteins (e.g., p53, cyclins, and cell cycle dependent kinase inhibitors (CDKIs)); angiogenesis (e.g., vascular endothelial growth factor (VEGF)); and antiapoptosis (e.g., B-cell lymphoma 2 (bcl-2), B-cell lymphoma-extra large (bcl-XL), X-linked inhibitor of apoptosis protein (XIAP), survivin, and FLICE-like inhibitory protein (FLIP)) [2].